These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24815322)

  • 1. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
    Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
    Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
    Obeng S; Yuan Y; Jali A; Selley DE; Zhang Y
    Eur J Pharmacol; 2018 May; 827():32-40. PubMed ID: 29530590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
    Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
    Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.
    Yuan Y; Elbegdorj O; Beletskaya IO; Selley DE; Zhang Y
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5045-8. PubMed ID: 23948248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
    Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
    Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
    Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
    ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.
    Pagare PP; Obeng S; Huang B; Marcus MM; Nicholson KL; Townsend AE; Banks ML; Zhang Y
    ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1197-1209. PubMed ID: 36407950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.
    Altarifi AA; Yuan Y; Zhang Y; Selley DE; Negus SS
    Psychopharmacology (Berl); 2015 Feb; 232(4):815-24. PubMed ID: 25178814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
    Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
    Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
    Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
    Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
    Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
    ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.
    Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Zhang F; Stevens DL; Beletskaya IO; Scoggins KL; Zhang Z; Gerk PM; Selley DE; Akbarali HI; Dewey WL; Zhang Y
    J Med Chem; 2012 Nov; 55(22):10118-29. PubMed ID: 23116124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.
    Márki A; Monory K; Otvös F; Tóth G; Krassnig R; Schmidhammer H; Traynor JR; Roques BP; Maldonado R; Borsodi A
    Eur J Pharmacol; 1999 Oct; 383(2):209-14. PubMed ID: 10585536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
    Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
    J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
    Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
    J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.
    Pagare PP; Li M; Zheng Y; Kulkarni AS; Obeng S; Huang B; Ruiz C; Gillespie JC; Mendez RE; Stevens DL; Poklis JL; Halquist MS; Dewey WL; Selley DE; Zhang Y
    J Med Chem; 2022 Mar; 65(6):5095-5112. PubMed ID: 35255685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Profile of Naldemedine, a Peripherally Acting
    Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
    Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
    Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
    Wang D; Raehal KM; Bilsky EJ; Sadée W
    J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.